Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
Phase 1
128
about 12 months
18–55
1 site in KS
About this study
Researchers are testing a treatment called VX-581 to see if it's safe and how it works in healthy people. The trial will last for 345 days, with participants receiving either a placebo or VX-581.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take VX-581
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Secondary: Part A: Maximum Observed Plasma Concentration (Cmax) of VX-581, Part B: Maximum Observed Plasma Concentration (Cmax) of VX-581
Respiratory